Abstract

Objective of this study was to explore the effectiveness and safety of roxadustat in the treatment of hemodialysis and renal anemia. Clinical data of 84 individuals having maintenance hemodialysis and renal anemia treated in the dialysis department of our hospital from October 2022 to October 2023 were selected for the analysis and were randomly divided into two groups, control and observation groups each with 42 individuals (n=42). Control group was given intravenous injection of recombinant human erythropoietin while the observation group was given oral roxadustat treatment. The treatment course for both groups was 12 w. After treatment, the clinical effects and various indicators of the two groups of patients were compared, including anemia indicators (red blood cells, hemoglobin and hemocrit value), iron metabolism indicators (serum ferritin, transferrin saturation and transferrin) and the incidence of adverse reactions was analyzed comparatively. After treatment, the drug efficacy of the observation group was higher than that of the control group (p<0.05). Similarly, after treatment anemia indicators and iron metabolism indicators in both groups were higher than before treatment (p<0.05). The adverse reactions of the observation group were less than those of the control group (p<0.05). Roxadustat has a significant effect in treating renal anemia which can effectively improve anemia indicators and iron metabolism indicators. Further, it can also promote blood circulation, ensure the balance of blood and iron metabolism and reduce the incidence of adverse reactions.